U.S. FDA Accepts NDA And Grants Priority Review For Takeda's Oveporexton (Tak-861) As A Potential First-In-Class Therapy For Narcolepy Type 1
10/02/2026 08:00
Takeda Pharmaceutical Co Ltd 4502.T: TAKEDA PHARMACEUTICAL CO LTD - U.S. FDA ACCEPTS NDA AND GRANTS PRIORITY REVIEW FOR TAKEDA'S OVEPOREXTON (TAK-861) AS A POTENTIAL FIRST-IN-CLASS THERAPY FOR NARCOLEPY TYPE 1 Source text: ID:nTSnj870bc Further company coverage: 4502.T
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)